KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Merck (MRK) Long-Term Debt Repayments (2016 - 2026)

Merck has reported Long-Term Debt Repayments over the past 17 years, most recently at $1.1 billion for Q1 2026.

  • Quarterly Long-Term Debt Repayments fell 54.4% to $1.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, down 62.39% year-over-year, with the annual reading at $2.5 billion for FY2025, 94.03% up from the prior year.
  • Long-Term Debt Repayments was $1.1 billion for Q1 2026 at Merck, up from $2.0 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $2.5 billion in Q1 2025 and troughed at $1.0 million in Q4 2022.
  • The 5-year median for Long-Term Debt Repayments is $539.0 million (2024), against an average of $687.6 million.
  • Year-over-year, Long-Term Debt Repayments plummeted 99.92% in 2023 and then skyrocketed 75000.0% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $1.0 million in 2022, then skyrocketed by 200.0% to $3.0 million in 2023, then soared by 17866.67% to $539.0 million in 2024, then crashed by 99.63% to $2.0 million in 2025, then surged by 56900.0% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Long-Term Debt Repayments are $1.1 billion (Q1 2026), $2.0 million (Q4 2025), and $1.0 million (Q3 2025).